AM I ELIGIBLE?

Potential Candidate Scenario

Unique Identifier:

1. Does the patient have NYHA class II or III heart failure?


2. Does the patient have an EF≤35%


3. Has the patient been stable on GDMT for a minimum of 4 weeks?


4. The patient does NOT have a planned Ventricular Assist Device (VAD)
implant, organ transplant, or ablation procedure in the next 6-months?

Yes
Yes
Yes
Yes
No
No
No
No

You must have all YES answers to qualify as a potential candidate for ANTHEM HFrEF

WHY SHOULD I VOLUNTEER?

By participating in a clinical study you can:

  • Take an active role in your own health care

  • Obtain expert medical care at leading healthcare facilities during the clinical trial 

  • Help others by contributing to medical research

†Before you join a clinical study you should know as much as possible about the study. It is important for you to feel very comfortable asking questions and receiving complete answers prior to deciding to participate or not in the study. You should feel comfortable not participating in the study if you so choose.

WHAT IS EXPECTED OF ME IF I PARTICIPATE?

1. SIGN THE CONSENT FORM after understanding details about the study including risks, benefits and your responsibility as a participant


2. COMPLETE ENROLLMENT AND EVALUATION STEPS, which will likely include:

  • Medical history and physical examination

  • Tests to check your overall health status (echocardiogram, blood and Holter Monitor 

  • Questionnaires

3. PARTICIPATE IN FOLLOW-UP VISITS

Return for clinical visits throughout the study. You will be reimbursed for travel associated with follow-up visits, which will include:

  • ART stimulation adjustments until therapy target established

  • Subsequent follow-up visits consisting of scheduled visits every 3 months after therapy adjustment during the first 12 months, and scheduled visits every 4 months thereafter
     

HOW LIKELY AM I TO RECEIVE INVESTIGATIONAL THERAPY?

YOU ARE MORE LIKELY TO RECEIVE ART THAN NOT RECEIVE ART IN THE CLINICAL TRIAL

 

Everyone in the clinical trial will continue receiving the best medical (drug) therapy available for heart failure from their doctor. In addition, 2 out of every 3 eligible patients will receive ART.

3 Eligible Patients

2 receive ART and drug therapy

1 receives drug therapy alone

Click here to watch a short video and learn more